Johnson & Johnson (NYSE:JNJ) managed to post a 7.5 percent boost to its bottom line despite flat second-quarter sales, but saw its stock slide on lowered guidance from problems with its over-the-counter drug unit.
The New Brunswick, N.J.-based health products conglomerate’s medical device and diagnostics business posted sales of $6.13 billion, up 4.1 percent compared with $5.89 billion during the same period last year.